News | August 13, 2024
Morepen Labs Q1 FY25 profit surges 147% to Rs. 36.17 Cr
Morepen Labs successfully raised Rs. 200 Crore through QIP
Morepen Labs successfully raised Rs. 200 Crore through QIP
EBITDA for Q1 FY25 is at Rs. 100 crore compared to Rs. 32 crore in the previous year
Q1FY25 Revenue from Operations grew by 15% to Rs. 177 crore
Revenue from Operations increased by 10.5% YoY to Rs. 7,567 crore with growth across the businesses
The comprehensive criteria encompasses evaluation of debt management, sales growth, earnings-per-share performance, as well as returns on equity
Research & Development (R&D) investments for the quarter stood at Rs. 392.5 crore which is 6.3% of its revenues
Our centers are performing as expected or even better
This strong performance was primarily on account of a one-time gain from the strategic collaboration between Biocon Biologics and Eris Lifesciences.
The company has seamlessly integrated the business acquired from Yash Pharma into Jagsonpal and are now confident of aligning the margins of the acquired business with that of Jagsonpal ahead of schedule
Expect the international business including CDMO business to pick-up in the second half of the financial year
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
